Unicycive Therapeutics receives Nasdaq bid price deficiency notice; 180 days to regain compliance

Unicycive Therapeutics, Inc.

Received Nasdaq notice on July 9, 2024 for bid price below $1.00 for 30 consecutive business days.
Has until January 6, 2025 to regain compliance by closing at $1.00+ for ten consecutive business days.
Stock continues trading on Nasdaq Capital Market under symbol UNCY; company may consider options.
If not compliant by Jan 6, 2025, may qualify for second 180-day period or face delisting with appeal rights.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.